Weight Loss Injections and Heart Disease: What the Evidence Shows

Does semaglutide actually protect the heart, or does it just reduce weight?

The SELECT trial, a large randomised controlled study involving more than 17,000 adults with obesity and pre-existing cardiovascular disease but without diabetes, found that weekly semaglutide 2.4mg cut the rate of major adverse cardiovascular events by 20% over roughly four years. Crucially, the benefit appeared early in the trial, before significant weight loss had occurred, which led researchers to conclude that the cardiovascular effect is at least partly independent of fat reduction alone. Reduced inflammation, improved blood pressure, and favourable changes in lipids are all thought to contribute.

The MHRA has formally recognised this evidence. Wegovy (semaglutide injection) now carries a UK licence specifically for reducing the risk of major cardiovascular events in adults with established cardiovascular disease and a BMI of 27 or above, used alongside a reduced-calorie diet and increased activity. This is a separate indication from weight management, both can apply to the same person. You can read the MHRA's public summary and the NHS medicines page for semaglutide for an accessible overview of what the medicine is authorised to do.

For tirzepatide (Mounjaro), the cardiovascular outcome data are still maturing. The SURMOUNT programme has enrolled thousands of adults, and dedicated heart-outcome studies are underway, but tirzepatide does not yet carry an equivalent cardiovascular-risk licence in the UK. Its current authorisation is for weight management and type 2 diabetes. A prescriber will explain which medicine best fits your situation.

If I already have heart disease, can I still be considered for a weight loss injection?

In many cases, yes, and depending on the specific conditions involved, a GLP-1 medicine may actually be clinically prioritised rather than avoided. The SELECT data described above were gathered specifically in people who already had heart disease, so there is real-world evidence for this population. That said, heart disease is not a single entity. Coronary artery disease, heart failure, arrhythmias, and recent cardiac events each carry different considerations, and your prescriber will want to understand yours.

There are a few specific points worth knowing. GLP-1 medicines can modestly raise resting heart rate in some people, which is relevant if you have certain arrhythmias. Blood pressure often falls during treatment, which is usually beneficial but needs monitoring if you already take antihypertensive medicines. If heart failure is part of your history, dedicated guidance applies, our page on weight loss injections and heart failure covers that ground separately.

Having a complex cardiac background means the clinical conversation is fuller, not shorter. At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the day it arrives. Patients with existing heart conditions are not waved through automatically; the prescriber reviews relevant health history and may ask follow-up questions before deciding.

Do weight loss injections affect blood pressure and cholesterol in people with heart disease?

They tend to, and generally in a favourable direction. Clinical trials consistently show reductions in systolic blood pressure of around 3–6 mmHg on average with GLP-1 treatment, alongside modest falls in LDL cholesterol and triglycerides and a small rise in HDL. For someone managing cardiovascular disease, these secondary changes can be meaningful additions to existing medication regimens, though they are not a substitute for statins, antiplatelets, or other evidence-based cardiac therapies.

The interaction with blood pressure medication is the practical thing to watch. If you are already on antihypertensives and blood pressure falls further during GLP-1 treatment, your GP or cardiologist may need to adjust your dose. This is one reason GP notification is built into our clinical process; it keeps your existing care team in the loop from the start.

For a broader look at how these medicines sit alongside other conditions that often accompany heart disease, our page on weight loss injections and kidney disease covers renal considerations that are relevant to many people with cardiovascular diagnoses, and if you have an inflammatory bowel condition alongside your heart history, our guidance on weight loss injections and Crohn's disease explains how that combination is approached clinically. And if you are exploring non-injection options for any reason, there is also useful background on weight loss medication that is not an injection.

What does a clinical assessment actually look like for someone with heart disease?

At the consultation stage, you will be asked about your cardiac history: what the diagnosis was, when it was made, what medications you currently take, and whether you have had any recent investigations. The prescriber uses this alongside your BMI, weight-related conditions, and other health information to decide which medicine (if any) is appropriate, and at what starting dose.

Weight loss injections are prescription-only medicines, and the prescriber's job is to balance the potential cardiovascular benefit against any specific cardiac risks that apply to you personally. Because kidney function also influences how these medicines are managed, anyone with both heart and renal concerns may find our page on whether you can take weight loss injections with kidney disease a helpful read before their consultation. If treatment is approved, your pen arrives in plain packaging via tracked next-working-day DPD delivery, keep it in the fridge door until injection day, and the prescriber's written guidance will accompany it. If you need dose increases later, those are reviewed clinically too, not applied automatically.

NICE recommends tirzepatide for weight management in adults meeting BMI and comorbidity thresholds, as set out in NICE technology appraisal TA1026. Cardiovascular disease is one of the qualifying comorbidities listed, so it can count towards NHS eligibility, though NHS access remains phased and criteria are strict. Private treatment through a regulated pharmacy like nume is an option for people who do not yet meet NHS thresholds or who prefer not to wait. Our guide to weight loss injections explains the full landscape, and our clinical team is available for aftercare questions seven days a week once treatment begins.